BPC-157
PEPTIDES+ MEMBERS ONLY
INDICATIONS FOR USE
BPC-157, or Body Protection Compound 157, is a synthetic peptide derived from a fragment of human gastric juice protein BPC. It is primarily used off-label for tissue healing, including musculoskeletal injuries, tendon repair, wound healing, and inflammation reduction. It is also being studied for gastrointestinal conditions such as ulcers and inflammatory bowel disease.
ROUTE OF ADMINISTRATION
Subcutaneous injection near the site of injury is most common.
Oral capsules or solutions are sometimes used for gastrointestinal conditions.
FORMULATIONS AND PRICING
| Medication | Formulation | Price |
|---|---|---|
| BPC-157 | 500mcg oral capsules (#30) | $90 |
| BPC-157 | 10mg vial (2mg/mL x 5mL) | $115 |
| BPC-157 | 20mg vial (4mg/mL x 5mL) | $210 |
| BPC-157 / TB-500 combination therapy | 500mcg-500mcg oral capsule (#30) | $150 |
COMMON INITIAL DOSING REGIMENS
For subcutaneous injections, a typical dose ranges from 200–500 mcg per injection, administered once or twice daily. Treatment duration varies but often lasts for 2–4 weeks, depending on the severity of the injury.
For oral administration, doses of 500–1,000 mcg daily are common, divided into two doses if necessary.
MECHANISM OF ACTION
BPC-157 interacts with the nitric oxide system, angiogenesis pathways, and growth factors, promoting cellular regeneration and tissue repair. It enhances collagen synthesis, accelerates wound healing, and improves blood vessel formation at the injury site. It also exerts cytoprotective effects on the gastrointestinal tract by stabilizing mucosal integrity and reducing inflammation.
Additionally, BPC-157 modulates inflammatory pathways, reducing pro-inflammatory cytokines and oxidative stress while supporting anti-inflammatory responses.
COMMON SIDE EFFECTS
Localized Reactions: Redness or irritation at the injection site, though rare.
Systemic Effects: Fatigue, nausea, or mild dizziness have been reported but are infrequent and dose-dependent.
Gastrointestinal: For oral forms, bloating or mild stomach discomfort may occur.
Severe Effects: BPC-157 is generally well-tolerated, with minimal evidence of severe adverse events. Long-term safety data is still limited, requiring caution in prolonged use.
CONTRAINDICATIONS
Absolute: Hypersensitivity to BPC-157 or excipients.
Relative: Patients with autoimmune diseases should use BPC-157 cautiously, as immune modulation by peptides could theoretically exacerbate certain conditions. It should also be avoided in pregnant or breastfeeding individuals due to insufficient safety data.
COMPARISON WITH TB-500 (THYMOSIN BETA-4)
BPC-157 and TB-500 are often combined for synergistic tissue healing effects, but their mechanisms of action differ. BPC-157 excels in angiogenesis, blood vessel repair, and tendon healing, whereas TB-500 focuses more on cellular migration and actin regulation for wound closure and flexibility.
BPC-157 is particularly effective for gastrointestinal issues and localized injuries, while TB-500’s systemic effects make it suitable for widespread soft tissue or inflammatory conditions. Additionally, BPC-157 has a faster onset of action and is better tolerated with fewer systemic effects.
MORE INFORMATION
FDA Safety Data Sheet not available (experimental peptide therapy)
Lee E. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021 [PubMed Link]
DeFoor MT. Injectable Therapeutic Peptides-An Adjunct to Regenerative Medicine and Sports Performance?. Arthroscopy. 2025 [PubMed Link]
Gwyer D. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019 [PubMed Link]
Chang CH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011 [PubMed Link]
Seiwerth S. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018 [PubMed Link]
Sikiric P. Stable Gastric Pentadecapeptide BPC 157: Prompt Particular Activation of Collateral Pathways. Curr Med Chem. 2023 [PubMed Link]
Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014 [PubMed Link]
Park JM. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020 [PubMed Link]
Sikiric P. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014 [PubMed Link]
Sikiric P. The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity. Pharmaceuticals (Basel). 2024 [PubMed Link]
Sikiric P. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des. 2020 [PubMed Link]
Sikiric P. Novel Cytoprotective Mediator, Stable Gastric Pentadecapeptide BPC 157. Vascular Recruitment and Gastrointestinal Tract Healing. Curr Pharm Des. 2018 [PubMed Link]
Sikiric P. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011 [PubMed Link
Sikiric P. Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?. Curr Pharm Des. 2017 [PubMed Link]
Sikiric P. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013 [PubMed Link]
Chang CH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014 [PubMed Link]